Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 39, Issue -, Pages 1437-1440Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST0391437
Keywords
antiprotease; cleavage susceptibility; elafin; inflammatory lung disease; innate host response; secretory leucoprotease inhibitor (SPLI)
Categories
Funding
- Alpha One Foundation
- Northern Ireland Chest, Heart and Stroke Association
- Northern Ireland RD Office
- Public Health Agency [COM/4275/10] Funding Source: researchfish
Ask authors/readers for more resources
SLPI (secretory leucoprotease inhibitor) and elafin represent the archetypal members of the WFDC [WAP (whey acidic protein) four disulfide core] family of proteins, and were originally characterized as protease inhibitors but have since been shown to possess a wider repertoire of activities. These functions include antimicrobial and immunomodulatory properties, suggesting that these proteins may play key roles in the innate immune response, and indicate the potential to develop some of these proteins as novel therapeutics. Susceptibility to host and bacterial protease cleavage may, however, limit the efficacy of recombinant protein therapies in diseases with a high protease burden such as CF (cystic fibrosis) lung disease. To overcome this problem, further refinement of the native proteins will be required to provide effective treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available